British biotechnology company Cambridge Antibody Technology said yesterday it had signed a strategic partnership with Elan to develop cures for human neurological disorders.

Cambridge said the alliance would capitalise on Elan's "proven track record in drug discovery and development of treatments for neurological disorders".